Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more
Immunovant Inc (IMVT) - Net Assets
Latest net assets as of December 2025: $986.13 Million USD
Based on the latest financial reports, Immunovant Inc (IMVT) has net assets worth $986.13 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.05 Billion) and total liabilities ($66.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $986.13 Million |
| % of Total Assets | 93.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | 80.71% |
| 10-Year Change | N/A |
| Growth Volatility | 142721.65 |
Immunovant Inc - Net Assets Trend (2018–2025)
This chart illustrates how Immunovant Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immunovant Inc (2018–2025)
The table below shows the annual net assets of Immunovant Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $707.45 Million | +14.52% |
| 2024-03-31 | $617.76 Million | +70.42% |
| 2023-03-31 | $362.49 Million | -22.84% |
| 2022-03-31 | $469.82 Million | +20.01% |
| 2021-03-31 | $391.48 Million | +316.16% |
| 2020-03-31 | $94.07 Million | +383041.90% |
| 2019-03-31 | $24.55K | +101.64% |
| 2018-03-31 | $-1.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunovant Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 123952300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.00K | 0.00% |
| Other Comprehensive Income | $1.46 Million | 0.21% |
| Other Components | $1.95 Billion | 275.00% |
| Total Equity | $707.45 Million | 100.00% |
Immunovant Inc Competitors by Market Cap
The table below lists competitors of Immunovant Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hillenbrand Inc
NYSE:HI
|
$2.23 Billion |
|
Viscofan
MC:VIS
|
$2.24 Billion |
|
NET ONE SYSTEMS
MU:NOX
|
$2.24 Billion |
|
The Andersons Inc
NASDAQ:ANDE
|
$2.24 Billion |
|
Van Lanschot NV
AS:VLK
|
$2.23 Billion |
|
THK Co. Ltd
PINK:THKLF
|
$2.23 Billion |
|
Greif Bros Corporation
NYSE:GEF
|
$2.23 Billion |
|
FOUR CORNERS PROPERTY TR.
F:4Z1
|
$2.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunovant Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 617,757,000 to 707,447,000, a change of 89,690,000 (14.5%).
- Net loss of 413,840,000 reduced equity.
- New share issuances of 450,000,000 increased equity.
- Other comprehensive income decreased equity by 449,000.
- Other factors increased equity by 53,979,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-413.84 Million | -58.5% |
| Share Issuances | $450.00 Million | +63.61% |
| Other Comprehensive Income | $-449.00K | -0.06% |
| Other Changes | $53.98 Million | +7.63% |
| Total Change | $- | 14.52% |
Book Value vs Market Value Analysis
This analysis compares Immunovant Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | $-0.15 | $25.10 | x |
| 2019-03-31 | $0.00 | $25.10 | x |
| 2020-03-31 | $2.18 | $25.10 | x |
| 2021-03-31 | $4.46 | $25.10 | x |
| 2022-03-31 | $4.28 | $25.10 | x |
| 2023-03-31 | $2.95 | $25.10 | x |
| 2024-03-31 | $4.47 | $25.10 | x |
| 2025-03-31 | $4.67 | $25.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunovant Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-58.50%) is below the historical average (-36.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-136.59 Million |
| 2019 | -1.83% | 0.00% | 0.00x | 16.50x | $-2.91K |
| 2020 | -70.57% | 0.00% | 0.00x | 1.16x | $-75.79 Million |
| 2021 | -27.44% | 0.00% | 0.00x | 1.05x | $-146.58 Million |
| 2022 | -33.36% | 0.00% | 0.00x | 1.10x | $-203.71 Million |
| 2023 | -58.20% | 0.00% | 0.00x | 1.12x | $-247.21 Million |
| 2024 | -41.98% | 0.00% | 0.00x | 1.08x | $-321.11 Million |
| 2025 | -58.50% | 0.00% | 0.00x | 1.10x | $-484.58 Million |
Industry Comparison
This section compares Immunovant Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunovant Inc (IMVT) | $986.13 Million | 0.00% | 0.07x | $2.23 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |